卡泊三醇联合倍他米松气雾泡沫剂治疗银屑病皮肤疼痛的真实世界疗效
结果显示PASI、手掌靶皮损PGA及皮肤疼痛强度均显著改善(P<0.001),疼痛阈值升高,提示该制剂可同时改善皮损与缓解皮肤疼痛。
要点
- 卡泊三醇联合倍他米松气雾泡沫剂每日一次治疗4周可显著改善银屑病皮损。
- 该治疗可显著降低皮肤疼痛强度并提高手掌皮损疼痛阈值。
- 真实世界研究提示该制剂对伴手掌皮损的银屑病患者皮肤疼痛有效。
核心结论
- 卡泊三醇联合倍他米松气雾泡沫剂可能是一种有效的局部抗银屑病治疗,不仅改善皮肤病变,还能缓解皮肤疼痛,从而有助于改善患者生活质量。
研究设计与样本
- 真实世界4周前瞻性开放研究,未设赋形剂或润肤霜对照,在意大利坎帕尼亚大区三个皮肤科单位进行。
- 治疗为每日一次应用卡泊三醇联合倍他米松气雾泡沫剂,疗程4周。
- 评估指标包括PASI、手掌区域靶皮损PGA、通过Pain Qualities Assessment Scale问卷评估主观皮肤疼痛特征及通过压力数字痛觉计测量手掌银屑病皮损皮肤疼痛阈值。
主要发现
- 治疗4周后PASI显著改善(均值:基线6.5±2.1 vs 治疗后2.3±1.6,P<0.001)。
- 手掌皮损PGA显著改善(均值:基线3.6 vs 治疗后1.7,P<0.001)。
- 皮肤疼痛平均强度评分从7.6降至1.3(P<0.001)。
- 皮肤疼痛性质中,intense、sensible、aching和unpleasant的降低幅度最大(基线至治疗后变化分别为6.3、6.3、6.1和5.8)。
- 治疗后手掌皮损疼痛阈值升高。
临床怎么用
- 对于伴手掌皮损且有皮肤疼痛的成人银屑病患者,可考虑使用卡泊三醇联合倍他米松气雾泡沫剂每日一次治疗4周以改善皮损和疼痛。
局限性
- 本研究为开放研究,未与赋形剂或润肤霜进行对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/OBJECTIVE: Although 40% of psoriasis patients reported skin pain, this symptom is often underestimated. A new formula of calcipotriol plus betamethasone dipropionate (Cal/BD) has been recently approved for psoriasis treatment. Therefore, we aimed to evaluate the efficacy of Cal/BD aerosol foam on skin pain of patients with plaque psoriasis. METHODS: A real-life 4-week prospective, open study on Cal/BD aerosol foam (not compared to vehicle or emollient cream) was performed in adult psoriasis patients attending three Dermatology units located in Campania region, Italy, between March and October 2018. Inclusion criteria were a history of skin pain over the last week and psoriatic involvement of the palmar area. Before (t0) and after a course of once daily application of Cal/BD aerosol foam for 4 weeks (t1), the following items were evaluated: Psoriasis Area and Severity Index (PASI), Physician Global Assessment (PGA) index of target plaque on palmar region, subjective skin pain features through Pain Qualities Assessment Scale questionnaire and skin pain threshold measured by pressure digital algometer at palmar psoriatic plaques. RESULTS: Seventy-five patients (43 male, mean age of 43.2 years) were enrolled. After 4 weeks of therapy with Cal/BD aerosol foam, a significant improvement in both PASI (mean: 6.5 ± 2.1 at t0 vs. 2.3 ± 1.6 at t1) and palmar plaques PGA (mean: 3.6 at t0 vs. 1.7 at t1) was observed (P < 0.001). The mean intensity score of skin pain decreased from 7.6 to 1.3 (P < 0.001); among skin pain qualities, intense, sensible, aching and unpleasant showed the highest rate of reduction (t0-t1: 6.3, 6.3, 6.1 and 5.8, respectively). Pain threshold of palmar skin lesions increased at t1. CONCLUSIONS: Our real-life study suggested that Cal/BD aerosol foam may represent a valid topical anti-psoriatic treatment, not only improving skin lesions, but also relieving cutaneous pain, thus contributing to ameliorate patients' quality of life.
引用
- Gallo L, Megna M, Cirillo T, et al. Psoriasis and skin pain: real-life effectiveness of calcipotriol plus betamethasone dipropionate in aerosol foam formulation. J Eur Acad Dermatol Venereol. 2019. PMID: 30767288. doi:10.1111/jdv.15488
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。